PDA vs TB-500
Both PDA and TB-500 are used for recovery and anti-inflammatory. Here's how their evidence, dosing, and regulatory status actually compare.
PDA
Evidence C+Pentadeca Arginate (PDA)
A 15-amino-acid arginate analog developed as a more stable, sometimes more bioavailable alternative to BPC-157. Limited published research; popular among compounding pharmacies in 2025–2026.
View full PDA profile →TB-500
Evidence BThymosin Beta-4 Fragment
A synthetic fragment of thymosin beta-4 that promotes cell migration, blood vessel formation, and tissue repair. Often stacked with BPC-157 as the 'Wolverine Stack.'
View full TB-500 profile →Side-by-Side
| Attribute | PDA | TB-500 |
|---|---|---|
| Evidence Grade | C+ | B |
| FDA Status | Not FDA-approved — newer compounded analog of BPC-157 | Not FDA-approved — Category 2 (reclassification to Cat 1 expected 2026) |
| Typical Dose | 200–500 mcg daily (subcutaneous) | 2 mg twice weekly (subcutaneous) |
| Clinics Indexed | 41 | 183 |
| Categories | recovery, anti-inflammatory | recovery, anti-inflammatory |
Key reported benefits — PDA
- ✓Tissue repair
- ✓Anti-inflammation
- ✓Potentially better stability than BPC-157
Key reported benefits — TB-500
- ✓Wound healing
- ✓Anti-inflammation
- ✓Tissue regeneration
- ✓Flexibility
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.